Name | Position | Country | Term | Time in Office |
Brandon M. Henry | Chair | US | 1st | 2022 03 - 2024 12 |
Julien Favresse | Member | BE | ||
M. Michael Gromiha | Member | IN | ||
Giuseppe Lippi | Member | IT | ||
Mario Plebani | Member | IT | ||
Jeffrey SoRelle | Member | US | ||
Eric P H Yap | Member | SG |
A. EXECUTIVE SUMMARY
The emergence of novel SARS-CoV-2 variants of concern such as the new Omicron (B.1.1.529), which possess high and unprecedented mutational profile, represents an urgent new threat to global pandemic response efforts. Due to the large number of mutations across the Omicron genome, there is urgent need for global collaboration to investigate the impact of new variants on the spectrum of SARS-CoV-2 diagnostics and ensure the validity and continuity of COVID-19 testing (molecular, antigenic and serological). Among the new VoCs, Omicron has clearly demonstrated the potential for new lineages with significant antigenic drift to emerge in the coming months and years, and the need establish priorities and actions plans that can be implemented when such variants arise and spread rapidly all around the world. Thus, a SARS-CoV-2 Variants Working Group (WG) within the IFCC Task Force on COVID-19 is being established, focusing on developing the best strategies to address the impact of new variants on laboratory diagnosis and monitoring of COVID-19 infection and disease.
B. SCOPE
The aim of this group is to support the overall mission of IFCC Task Force on COVID-19 by strategizing and addressing urgent issues related to impact of variants of concern on COVID-19 diagnostics. Terms of the reference are as follows:
C. MANDATE
With the support of the President of the IFCC, the IFCC Executive Committee, and IFCC COVID-19 Taskforce Chair, the IFCC WG on SARS-CoV-2 variants is now established within the IFCC Task Force on COVID-19. The group shall remain active, as needed, to respond to newly emerging variants until the dissipation of the pandemic, or until terminated by the President of the IFCC. The SARS-CoV-2 Variants Working Group will report directly to IFCC COVID-19 Taskforce Chair and to the President of the IFCC.
Dr. Brandon M. Henry
The Heart Institute
Cincinnati Children’s Hospital Medical Center
3333 Burnet Ave.
Cincinnati, OH 45229
USA
E-mail: Brandon.Henry@cchmc.org